Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › relacorilant

relacorilant

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of relacorilant

3 trials tracked of relacorilant: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 21 citations.

3Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 1
  1. Phase 3 A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Completed · 21 cited
  2. Phase 3 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas Completed
  3. Phase 2 Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Relacorilant maintained hypertension control versus placebo in adults with endogenous hypercortisolism
Drug Pipeline RCT
Relacorilant maintained hypertension control versus placebo in adults with endogenous hypercortisolism New Drug Helps Control High Blood Pressure in Cushing's
This phase 3 randomised-withdrawal study enrolled 152 adults with endogenous hypercortisolism and hypertension or hyperglycaemia.
Imagine your body is stuck in a permanent "fight or flight" mode.
Apr 24, 2026
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer
Oncology RCT
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer New Drug Combo Extends Survival for Tough Ovarian Cancer Cases
In a phase 3 randomised controlled trial of 381 patients with platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel significan…
This combination offers a new, simpler option for patients who have run out of standard treatments.
Apr 20, 2026